Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.

ABSTRACT:

Importance

To date, the risk of developing second primary cancers (SPCs) after the first primary melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs).

Objective

To assess differences in the risk of SPCs in patients with primary melanoma before (2005-2010) and after (2011-2016) the introduction and approval of ICIs.

Design, setting, and participants

Population-based cohort study using the Surveillance, Epidemiology, and End Results database from January 2005 to December 2016 of patients diagnosed with metastatic melanoma. Data were analyzed from January 4 to June 30, 2020.

Exposures

Receipt of immunotherapy or other anticancer agents.

Main outcomes and measures

The primary outcome was the development of second primary cancers in

SUBMITTER: Deng W 

PROVIDER: S-EPMC7726633 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature